Marginal note:Duty to publicize clinical trial information
21.71 The holder of a therapeutic product authorization referred to in paragraph 30(1.2)(c) shall ensure that prescribed information concerning the clinical trial is made public within the prescribed time and in the prescribed manner.
- 2014, c. 24, s. 3
- 2019, c. 29, s. 168
Amended by S.C. 2019, c. 29, s. 168, in force on May 23, 2020